Physician profile
Travis S Shivers
NPI 1023404258
$1,239.60
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $445 · 2021: $77.70 · 2022: $80.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $134.55 | 2019-2021 | |
| Amgen INC. | $129.35 | 2019-2020 | |
| Lilly USA, LLC | $111.70 | 2019-2020 | |
| Astellas Pharma US INC | $99.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.12 | 2019-2020 | |
| Novo Nordisk INC | $88.42 | 2019-2020 | |
| Pfizer INC. | $88.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $77.55 | 2019-2022 | |
| Glaxosmithkline, LLC. | $73.11 | 2019-2020 | |
| Allergan, INC. | $66.21 | 2019-2021 | |
| Abbvie INC. | $62.54 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $60.38 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $36.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.88 | 2019 | |
| Seqirus USA INC | $30.68 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $16.70 | 2019 | |
| Tris Pharma INC | $14.41 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.09 | 2019 | |
| Cranial Technologies, INC | $13.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Shivers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.